Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 5/20 | 0.41 |
| ▸ | DRD4 | P21917 | 5/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235983 | 1.00 | ESR2 (0.50) | ESR2DRD2DRD3DRD4OPRK1 | |
| SCHEMBL14409327 | 1.00 | ESR2 (0.50) | ESR2DRD2DRD3DRD4OPRK1 | |
| SCHEMBL5234926 | 1.00 | ESR2 (0.50) | ESR2DRD2DRD3DRD4OPRK1 | |
| SCHEMBL12168265 | 0.83 | ESR2 (0.61) | ESR2DRD2DRD3DRD4OPRK1 | |
| SCHEMBL15858171 | 0.83 | ESR2 (0.61) | ESR2DRD2DRD3DRD4OPRK1 | |
| SCHEMBL17090670 | 0.78 | — | — | |
| SCHEMBL3726820 | 0.77 | ESR2 (0.46) | ESR2DRD2DRD3DRD4OPRK1 | |
| SCHEMBL14409518 | 0.77 | ESR2 (0.44) | ESR2DRD2DRD3DRD4OPRK1 | |
| SCHEMBL21447810 | 0.75 | BRD4 (0.40) | — | |
| SCHEMBL23474196 | 0.74 | DRD2 (0.56) | DRD2DRD3DRD4OPRK1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439841-B1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-7196076-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1439841-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040198717-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2004-10-07 | — | — | US | disclosed |
| EP-1439841-A2 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003034987-A2 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198717-A1 | Androgen receptor modulators and methods of use thereof | AR, SHBG, FSHR | ESR2 23/4885DRD2 4161/4885DRD3 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.